Ownership and insider activity for Cue Biopharma, Inc. (CUE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.
Price
| Price | $34.17 |
| Market Cap | $90M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.9M | $63.5M | $20.8M | $44.3M | $74.9M | $64.4M | $51.6M | $48.5M | $22.5M | $27.1M |
| Short-term Investments | $50033 | $50068 | $18.4M | $15.1M | $10.0M | 0 | $24.7M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $754898 | $1.4M | $3.1M | $57000 | $1.7M | $945000 | $7.4M |
| Inventory | 0 | $225500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $15.1M | $65.1M | $40.6M | $61.0M | $87.5M | $68.5M | $77.2M | $51.5M | $25.1M | $37.0M |
| Property, Plant & Equipment | $1.0M | $1.7M | $2.8M | $7.2M | $8.9M | $11.9M | $10.7M | $7.1M | $4.8M | $4.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $175000 | 0 | $11667 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $16.3M | $67.0M | $45.4M | $71.6M | $99.5M | $83.4M | $91.3M | $61.5M | $32.2M | $42.2M |
| Accounts Payable | $523811 | $1.3M | $2.0M | $882666 | $2.1M | $2.6M | $2.7M | $3.5M | $2.8M | $3.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $2.0M | $2.0M | $4.0M | $4.3M | 0 |
| Total Current Liabilities | $1.1M | $5.3M | $6.2M | $11.7M | $16.3M | $12.8M | $11.5M | $17.1M | $13.7M | $13.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $8.0M | $4.2M | 0 | 0 |
| Total Liabilities | $1.1M | $5.3M | $11.4M | $17.0M | $20.6M | $17.9M | $25.6M | $24.4M | $14.7M | $15.8M |
| Retained Earnings | -$9.6M | -$32.8M | -$71.8M | -$108.5M | -$153.3M | -$197.4M | -$250.5M | -$301.2M | -$341.9M | -$368.5M |
| Total Equity | $15.2M | $61.6M | $34.0M | $54.6M | $78.9M | $65.5M | $65.7M | $37.1M | $17.5M | $26.4M |
| Total Debt | 0 | $2.5M | 0 | $5.8M | $7.1M | $12.0M | $19.3M | $14.7M | $8.9M | $4.2M |
| Net Debt | -$15.0M | -$61.1M | -$39.2M | -$53.6M | -$77.7M | -$52.3M | -$57.0M | -$33.8M | -$13.6M | -$22.9M |
| Working Capital | $14.1M | $59.7M | $34.4M | $49.4M | $71.2M | $55.7M | $65.6M | $34.4M | $11.4M | $23.5M |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 2.74 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -11.88 |
Profitability
| Return on Equity | -100.64% |
| Return on Invested Capital | -86.59% |
| Return on Assets | -63.02% |
| Gross Margin | 100.00% |
| Operating Margin | -96.56% |
| Net Margin | -96.85% |
Related companies: BRNS · COEP · EQ · IOBT · IPSC · MDCX · NRXP
Explore sector: Healthcare · Biotechnology
More sections of CUE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks